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Abstract: Impaired rate-dependent depression of the Hoffman reflex (HRDD) is a potential biomarker
of impaired spinal inhibition in patients with painful diabetic neuropathy. However, the optimum
stimulus-response parameters that identify patients with spinal disinhibition are currently unknown.
We systematically compared HRDD, performed using trains of 10 stimuli at five stimulation fre-
quencies (0.3, 0.5, 1, 2 and 3 Hz), in 42 subjects with painful and 62 subjects with painless diabetic
neuropathy with comparable neuropathy severity, and 34 healthy controls. HRDD was calculated
using individual and mean responses compared to the initial response. At stimulation frequencies
of 1, 2 and 3 Hz, HRDD was significantly impaired in patients with painful diabetic neuropathy
compared to patients with painless diabetic neuropathy for all parameters and for most parameters
when compared to healthy controls. HRDD was significantly enhanced in patients with painless
diabetic neuropathy compared to controls for responses towards the end of the 1 Hz stimulation
train. Receiver operating characteristic curve analysis in patients with and without pain showed
that the area under the curve was greatest for response averages of stimuli 2–4 and 2–5 at 1 Hz,
AUC = 0.84 (95%CI 0.76–0.92). Trains of 5 stimuli delivered at 1 Hz can segregate patients with
painful diabetic neuropathy and spinal disinhibition, whereas longer stimulus trains are required to
segregate patients with painless diabetic neuropathy and enhanced spinal inhibition.
Keywords: diabetic neuropathy; pain; spinal disinhibition; H-reflex
1. Introduction
There is increasing recognition that processes within the spinal cord are key to modu-
lating neuropathic pain, through amplification or suppression of peripheral nociceptive
inputs. The neurotransmitters γ-aminobutyric acid (GABA) and glycine play a critical
inhibitory role in regulating spinal nociceptive processing [1–3]. Diabetic rodents exhibiting
behavioural markers of pain paradoxically show elevated basal and stimulus-evoked levels
of the inhibitory neurotransmitter GABA in spinal CSF [4,5] and a reversal of GABAA re-
ceptor function, from inhibitory to excitatory, has been demonstrated [4]. Current evidence
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indicates a reduction in potassium (K+)/chloride (Cl−) symporter KCC2 in the dorsal
spinal cord and subsequent elevation in intracellular/intraneural chloride concentration,
which renders GABA, acting via GABAA receptors, less hyperpolarising and potentially
depolarising [4]. This pro-nociceptive alteration is termed spinal disinhibition [6].
A potential biomarker of spinal disinhibition is rate-dependent depression of the
H-reflex [7,8]. The H-reflex enables the study of proximal peripheral nerve conduction
and provides insight into the function of spinal modulatory systems [9]. The H-reflex
is modified when exposed to successive stimulations resulting in a decrease in the H-
wave amplitude relative to the amplitude of the original H-wave [10] and is termed
rate-dependent depression (HRDD). Although the precise neurophysiological substrate
remains unclear, and indeed may be multifactorial, the magnitude of HRDD is known
to be dependent on the function of inhibitory mechanisms in the spinal cord [11–13].
Accordingly, a loss of inhibition that accompanies the spasticity seen in animal models of
spinal cord injury and following spinal cord injury in humans, results in a reduction in the
magnitude of HRDD [10,14].
Both a loss of HRDD and altered behavioural indices of neuropathic pain are seen
in rodent models of diabetes [4]. Moreover, both are also associated with reversal of
GABAA inhibition, suggesting that they share a common pathogenic mechanism; spinal
disinhibition [4,7]. Our recent research has demonstrated that loss of HRDD occurs in
patients with painful diabetic neuropathy [8,15]. We suggest that loss or attenuation of
HRDD may serve as a marker of spinal inhibitory dysfunction in a sub-set of patients where
spinal disinhibition contributes to neuropathic pain. Thus, a potential clinical application
of HRDD could be to enable identification of patients with painful diabetic neuropathy in
whom the pain has either dominant peripheral or spinal drive, to allow mechanistically
informed clinical trials and predict response to specific anti-neuropathic pain medications.
Currently, it is not known which HRDD parameters best distinguish between these
sub-groups of patients. In preclinical and clinical studies, the stimulation trains used for
eliciting HRDD have been of variable length and frequency, and HRDD has been calculated
using a variety of individual or average response sequences. In our proof-of-concept
clinical study in patients with diabetes, trains of three stimuli were delivered [8]. HRDD
was calculated as the amplitude of stimulus 1 compared to stimulus 3, as qualitatively
it was observed that H-reflex depression was greater at stimulus 3 than stimulus 2 [8].
Stimulation at 1 Hz produced the greatest separation between patients with and without
painful neuropathy. In a follow-up study of a larger cohort of patients with diabetic
neuropathy [15], trains of 10 stimuli were delivered at 1 Hz and the response to the initial
stimulus was compared to the mean of all subsequent responses to mitigate against random
and time course fluctuations.
Using signal detection theory methods, the purpose of the current investigation was to
systematically assess which stimulation and response parameters best distinguish between
patients with and without pain. This is critical to allow wider application of this technique
as a balance needs to be struck between obtaining the most useful and relevant information
with the practicalities of performing and tolerability of the investigation. To explore the
utility of HRDD as a biomarker in painful diabetic neuropathy, we compared response
trains at increasing stimulus frequencies, with the aim of defining the optimal parameters
to segregate patients with spinal inhibitory dysfunction as a dominant pain mechanism.
2. Materials and Methods
2.1. Ethics and Recruitment
Patients were recruited from secondary care diabetes clinics at one NHS trust over
a period of 24 months. Convenience sampling was used, and all eligible patients were
given the opportunity to take part in the research study. Control subjects were recruited via
hospital and University advertisements. Written informed consent was obtained for each
participant. Study conduct adhered to the tenets of the Declaration of Helsinki and Research
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Ethics Committee approval was granted on 28 February 2017 (Project identification code:
220627, East Midlands, Leicester South Research Ethics Committee, reference 17/EM/0076).
2.2. Participants and Demographics
Patients with painful diabetic neuropathy (n = 53), patients without painful diabetic
neuropathy (n = 75) and healthy control subjects (n = 36) were studied. The H-reflex was
absent in 24 patients with diabetes (10 with type 1 and 14 with type 2 diabetes) and 2 control
subjects, and these subjects were excluded from further assessment. Detailed demographic
data, medical history and current medications, age, gender, ethnicity, type and duration of
diabetes, co-morbidities, height, weight, blood pressure, HbA1c, lipids and renal function
were documented. Other common causes of neuropathy were excluded based on a family
history as well as testing for serum B12, folate, immunoglobulins, electrophoresis and anti-
nuclear antibody. Participants underwent assessment of small and large nerve fibres using
corneal confocal microscopy, nerve conduction studies and thermal thresholds along with
assessment of HRDD. Visual analogue scale (VAS) pain scores (0–100) recording current,
average and maximum pain ratings over the previous 24 h were documented. Patients
were stratified into painful (DPN+) and painless (DPN-) cohorts based on the Toronto
consensus that “the symptoms are distal, symmetrical, often associated with nocturnal
exacerbations, and commonly described as prickling, deep aching, sharp, like an electric
shock, and burning with hyperalgesia” for greater than 3 months, consistent with the
requirement of pain chronicity defined by the International Association for the Study of
Pain (IASP) [16]. All patients with a current, average or maximum VAS pain score >0 were
placed in the pain cohort.
2.3. Nerve Conduction and H-Reflex Studies
Nerve conduction and H-reflex studies were performed using a DANTEC Keypoint
system (Dantec Dynamics Ltd., Bristol, UK). Participants were sat semi-recumbent at 45◦
with limb temperature maintained between 32–35◦. Sural sensory amplitude (SNAP) and
conduction velocity (SNCV) along with peroneal motor nerve amplitude (PMNAP) and
conduction velocity (PMNCV) were recorded. For H-reflex studies, tibial nerve stimulation
was performed using 1 ms square wave monophasic pulses delivered using surface silver-
silver chloride electrodes to the popliteal fossa. Surface silver-silver chloride recording
electrodes with a diameter of 9 mm were placed on the long axis of soleus. H-reflex
recruitment curves were obtained to determine peak-peak H-reflex maximal amplitude
(Hmax) by incrementing stimulation current by 1 mA. A minimal stimulation interval of
10 s was observed. For HRDD, a submaximal stimulus strength (to achieve a response of
75% of max) was used. A train of 10 stimuli were delivered (Figure 1) at 0.3, 0.5, 1, 2 and
3 Hz, giving 10 H-responses termed H1–H10 respectively. The frequency of the stimulation
trains were delivered in a pseudo-randomised order with a minimum inter-train interval of
10 s. HRDD was calculated as the individual response value expressed as a percentage of
response H1 or the mean of a group of responses, expressed as a percentage of response H1.
2.4. Corneal Confocal Microscopy
Participants underwent corneal confocal microscopy (CCM) using a laser scanning
corneal confocal microscope HRT III (Heidelberg Retinal Tomograph III Rostock Cornea
Module, Heidelberg Engineering, Heidelberg, Germany) for both eyes using an established
protocol [17]. Six images from the central cornea at the level of the sub basal nerve plexus
were analysed for each patient and control subject. Corneal nerve fibre density (CNFD,
total number of main nerves per square millimetre (no./mm2)), corneal nerve fibre length
(CNFL, total length of main nerves and nerve branches per square millimetre) (mm/mm2)
and corneal nerve branch density (CNBD, total number of nerves per square millimetre
(no./mm2)) were quantified.
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Figure 1. Example raw traces of H-reflex RDD in (A) healthy controls, (B) patients with diabetes 
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Figure 1. Example raw traces of H-reflex RDD in (A) healthy controls, (B) patients with diabetes
without neuropathic pain, and (C) patients with diabetes with neuropathic pain.
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2.5. Statistical Methods
Statistical analyses were performed using GraphPad Prism statistical software (Graph-
Pad Software Inc, La Jolla, CA, USA). Parametric data were analysed using unpaired t-test
or one-way ANOVA followed by Tukey’s multiple comparison to compare means between
groups. Non-parametric data were analysed using the Kruskal–Wallis test followed by
Dunn’s post hoc for multiple comparisons. The analysis of covariance (ANCOVA) (post hoc
least significant difference (LSD)) was used to compare variables between groups, while
statistically controlling for the effects of age. Receiver operating characteristic (ROC) curve
analyses were used to define the Wilson/Brown estimate of area under the ROC curve.
Optimal cut offs were determined using Youden’s index [18] and associated sensitivity and
specificity documented.
3. Results
3.1. Clinical, Demographic and Neuropathy Measures
Clinical and demographic characteristics are summarised in Table 1. In the painful
diabetic neuropathy group, 16 patients were taking anti-neuropathic pain medication as
monotherapy (six were taking selective serotonin reuptake inhibitors, four were taking
tricyclic medication, three were taking gabapentanoids and three were taking Duloxetine).
Patients with diabetes were older, with higher BMI and HbA1c compared to control
subjects. There was no significant difference in BMI or HbA1c between patients with
or without neuropathic pain. Sural amplitude, sural and peroneal conduction velocity,
corneal nerve fibre density and corneal nerve fibre length were all significantly lower in
patients with diabetes compared to controls. Cold detection and warm detection thresholds
were significantly impaired in patients with diabetes compared to controls. There was no
significant difference between patients with and without painful neuropathy in any of the
demographic parameters or measures of small and large fibre neuropathy.
3.2. HRDD Time-Course
To explore the time course of HRDD during stimulation trains in patients with dia-
betes and control subjects, analysis of individual stimulus responses and train averages
was performed at five stimulation frequencies (Table 2). There was no significant difference
at any stimulus number between patients with or without painful diabetic neuropathy
or between control subjects and either patient group at 0.3 Hz. With increasing stimulus
frequency, an increasing number of significant differences were seen. At 0.5 Hz, there
were significant differences in individual stimulus responses (H2, p = 0.006; H3, p ≤ H5,
p ≤ 0.001; H6, p ≤ 0.016) and train averages (mean H2–4, p = 0.0214; mean of H2–5,
p < 0.003; mean of H2–10, p < 0.018) between patients with and without painful neuropathy.
At 1, 2 and 3 Hz (Figure 2, Table 2), all individual and train averages between patients with
and without painful neuropathy were significantly different (p < 0.001 except for H2 at both
2 Hz (p < 0.034) and 3 Hz (p < 0.001)). There was a significant difference between patients
with painful neuropathy and control subjects at 1Hz (H2, H3, H4, H5 and H7, all p < 0.01),
2 Hz (H3, H4, H5, H6 and H10, all p < 0.05) and 3 Hz (stimulation numbers H2–10, all
p < 0.05). A significant difference was observed between patients without painful neuropa-
thy and controls for H2 at 0.5 Hz (p = 0.037) and at individual stimulus responses towards
the end of the train (H7, p = 0.012; H8, p = 0.004; H10, p = 0.003) and whole train average
(mean of H2–10, p = 0.018) at 1 Hz. No significant difference was seen between patients
without painful neuropathy and control subjects at 2 or 3 Hz.
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Table 1. Demographic and neuropathy parameters for patients with diabetes, with and without












(Female/Male) 18/24 18/44 20/14
Ethnicity
(White/Asian/Black) 32/8/2 46/13/3 25/7/2
Median ± Interquartile Range
Age (years) 61.5 (49.8–69.5) *** 65.0 (51.5–71) **** 46.5 (31–55)
Duration (years) 12.5 (4.8–20.3) 16.0 (10.0–23.3)





BMI (kg/m2) 29.2 (25.5–34.9) **** 27.3 (24.3–31.9) ** 23.8 (22.5–25.4)
SNAP (µV) 7.7 (3.7–15) *** 6.9 (4.3–11.5) **** 17.0 (15–22)
SNCV (m/s) 43.1 (40–46.7) *** 42.4 (40–46.7) **** 48.3 (45.2–51.9)
PMNAP (mV) 3.8 (2.4–5.7) 3.5 (2.4–5.9) * 4.9 (3.4–7.5)
PMNCV (m/s) 41.4 (38.1–43.7) **** 41.2 (38.6–44) **** 47.5 (43.4–50)
CDT (◦C) 27.8 (23.3–29.6) *** 28.0 (24.1–29.9) ** 29.8 (28.5–30.5)




past 24 h (0–100) 35.5 (15.8–64.5)
VAS Pain Maximum
past 24 h (0–100) 56 (30–80)
Mean ± SE
CNFD (no.mm2) ˆ 23.84 ± 1.84 *** 25.30 ± 1.31 *** 32.36 ± 1.59
CNFL (mm/mm2) ˆ 18.16 ± 1.563 *** 18.43 ± 1.11 *** 25.11 ± 1.35
CNBD (no.mm2) ˆ 46.64 ± 5.18 47.61 ± 4.20 59.74 ± 6.85
HRDD meanH2-10 @
1 Hz ˆ 60.40 ± 2.74 *** 34.92 ± 2.33 * +++ 43.46 ± 3.31
Non-parametric data are expressed as median ± interquartile range: Mann–Whitney or Kruskal–Wallis with
Dunn post hoc test. Parametric data are expressed as mean ± SE: ˆ ANCOVA values adjusted for age (post
hoc LSD). * p < 0.05 compared to controls ** p < 0.01 compared to controls *** p < 0.001 compared to controls
**** p < 0.0001 compared to controls. +++ p < 0.001 compared to painful diabetic neuropathy. BMI, body mass
index; SNAP, sural nerve amplitude; SNCV, sural nerve conduction velocity; PMNAP, peroneal motor nerve
amplitude; PMNCV, peroneal motor nerve conduction velocity; CDT, cold detection threshold; WDT, warm
detection threshold; VAS, visual analogue scale; CNFD, corneal nerve fibre density; CNFL, corneal nerve fibre
length; CNBD, corneal nerve branch density; HRDD, H-reflex rate-dependent depression.
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Table 2. Significance values for individual stimulus responses and train averages between patients with diabetes, with and
without pain, and control subjects at 0.3, 0.5, 1, 2 and 3 Hz. Between group means compared using one-way ANOVA and
Tukey’s post hoc multiple comparison. Data are expressed as p value determined by Tukey’s post hoc test.







Pain 0.177 0.552 0.551 0.417 0.366 0.273 0.906 0.077 0.177 0.279 0.272 0.229
Pain v
Control 0.868 0.673 0.955 0.940 0.692 0.960 0.906 0.786 0.941 0.793 0.944 0.979
No Pain v
Control 0.063 0.134 0.388 0.677 0.916 0.467 0.998 0.359 0.351 0.078 0.161 0.363
0.5 Hz
Pain v No
Pain 0.006 0.004 0.621 0.001 0.016 0.498 0.382 0.053 0.248 0.021 0.003 0.018
Pain v
Control 0.837 0.591 0.839 0.066 0.255 0.996 0.928 0.772 0.680 0.951 0.546 0.655
No Pain v
Control 0.037 0.074 0.262 0.356 0.541 0.434 0.191 0.245 0.763 0.051 0.075 0.175
1 Hz
Pain v No
Pain <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Pain v
Control <0.001 <0.001 <0.001 <0.001 0.079 0.006 0.310 0.080 0.057 <0.0001 <0.0001 <0.001
No Pain v
Control 0.236 0.147 0.256 0.233 0.183 0.012 0.004 0.055 0.003 0.125 0.117 0.018
2 Hz
Pain v No
Pain 0.034 <0.001 <0.0001 <0.0001 <0.0001 <0.0001 <0.001 <0.001 <0.001 <0.0001 <0.0001 <0.0001
Pain v
Control 0.236 0.031 0.006 0.050 0.009 0.103 0.317 0.108 0.039 0.016 0.014 0.018
No Pain v
Control 0.753 0.320 0.275 0.185 0.462 0.107 0.093 0.125 0.386 0.327 0.254 0.175
3 Hz
Pain v No
Pain <0.001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Pain v
Control 0.022 0.005 0.007 <0.001 0.001 0.002 0.009 0.002 0.016 0.002 <0.001 <0.001
No Pain v
Control 0.867 0.320 0.304 0.259 0.627 0.482 0.306 0.573 0.482 0.393 0.342 0.397
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 Figure 2. Group mean H wave amplitude responses to stimulus train at (A) 1 Hz, (B) 2 Hz and (C) 3 Hz in control subjects
(black circle/black line), patients with painful diabetic neuropathy (red circle/red line) and patients with painless diabetic
neuropathy (green circle/green line). Significance values detailed in Table 2.
3.3. ROC Curve Analysis
To determine the optimal cut-off for HRDD between patients with and without pain,
a ROC curve analysis was undertaken for both individual stimulus responses and average
stimulus responses at 1, 2 and 3 Hz (Figure 3). The Wilson/Brown area under the curve
was greatest for stimulus response averages H2–4 and H2–5 at 1 Hz, AUC = 0.84 (95%CI
0.76–0.92) with an optimal cut-off at 64.6 and 65.1 respectively. Increased sensitivity was
observed using stimulus response average H2–4 (52.4 compared to 47.6 using stimuli 2–5)
but greater specificity was seen using stimulus response average H2–5 (98.4 compared to
96.7 using stimuli 2–4) (Table 3). Analysis incorporating later responses did not improve
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AUC (1 Hz: H2–6, AUC = 0.82; H2–7, AUC = 0.82; H2–8, AUC = 0.81; H2–9, AUC = 0.80;
H2–10, AUC = 0.80).
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Figure 3. Receiver-operated characteristic (ROC) plots for HRDD at (A) 1 Hz, (B) 2 Hz, (C) 3 Hz in patients with painful
diabetic neuropathy versus patients with painless diabetic neuropathy using stimulus response H3 (orange line), average of
stimulus responses H2–4 (green line), average of stimulus responses H2–5 (blue line) and average of stimulus responses
H2–10 (pink line).
Table 3. Receiver-operated characteristic (ROC) analysis with area under the curve, optimal cut off and respective sensitivity
and specificity with 95% confidence interval, for H-reflex stimuli responses at 1, 2 and 3 Hz in patients with painful and
painless diabetic neuropathy. CI, confidence interval.
Optimal Cut Off Area under Curve 95%
CI
Sensitivity Specificity
95% CI 95% CI
1 Hz H3 45.73 0.8 78.57 75.420.72–0.89 63.19–89.70 62.71–85.54
1 Hz mean H2–3 58.93 0.82 88.52 64.290.73–0.90 78.16–94.33 49.17–77.01
1 Hz mean H2–4 49.65 0.84 78.57 77.050.76–0.92 63.19–89.70 64.50–86.85
1 Hz mean H2–5 49.13 0.84 78.57 77.050.76–0.92 64.06–88.29 65.09–85.81
1 Hz mean H2–10 57.49 0.8 50.34 96.720.72–0.89 34.19–65.81 88.65–99.60
2 Hz H3 29.81 0.74 84.85 59.620.64–0.85 69.04–93.35 46.07–71. 4
2 Hz mean H2–3 37.66 0.7 53.85 81.820.58–0.81 40.5–66.66 65.61–91.39
2 Hz mean H2–4 38.84 0.73 72.73 69.230.62–0.84 55.78–84.93 55.73–80.09
2 Hz mean H2–5 42.84 0.73 60.61 78.850.62–0.85 43.68–75.32 65.97–87.76
2 Hz mean H2–10 33.61 0.74 69.7 71.150.63–0.85 57.73–81.67 57.73–81.67
3 Hz H3 48.49 0.74 56.41 89.660.64–0.85 40.98–70.70 79.21–95.17
3 Hz mean H2–3 43.54 0.74 63.79 79.490.64–0.85 50.93–74.95 64.47–89.22
3 Hz mean H2–4 57.12 0.76 51.28 94.830.66–0.86 36.20–68.13 85.86–98.59
3 Hz mean H2–5 50.91 0.78 53.85 93.10.68–0.87 38.57–68.43 83.57–97.29
3 Hz mean H2–10 F 0.78 66.67 82.760.68–0.87 50.98–79.37 71.09–90.36
4. Discussion
We have previously demonstrated attenuated or enhanced HRDD in patients with
diabetes and painful or non-painful neuropathy, respectively [8,15]. In the present study,
we have defined HRDD stimulation and response parameters that best segregate patients
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with painful or non-painful diabetic neuropathy and determined optimal sensitivity and
specificity for HRDD to stratify patients based on the mechanistic basis of their pain.
HRDD refers to the degree of suppression of the H-reflex by repetitive stimulation
and increases in magnitude with increasing stimulation frequency [10]. In addition to this
phenomenon, we have demonstrated an increasing divergence of H-reflex responses in
patients with and without painful neuropathy at increasing stimulation frequencies. At a
frequency of 1 Hz, all individual stimulus responses throughout the train were significantly
different between patients with diabetes, with and without pain. The higher frequencies
of 2 and 3 Hz showed equally significant differentiation but did not add in terms of
distinguishing those with pain and no pain. The ROC analysis of full train averages
alongside individual response H3, and mean averages of responses H2–4 and H2–5 yielded
excellent discrimination [19] between patients with and without pain. In terms of patient
tolerability of the assessment, stimulation at 1 Hz is rarely uncomfortable and is more
acceptable than stimulation at higher frequencies and thus less likely to produce response
artifacts due to contraction of other lower limb muscles [20]. We have shown that optimal
discrimination between painful and painless diabetic polyneuropathy can be achieved
whilst abbreviating the stimulus train to five impulses.
In the current study, patients with diabetes were segregated based on the presence and
duration of characteristic neuropathic symptoms into those with pain versus those with no
pain [21,22]. It should be emphasised that the primary purpose was not to define HRDD as
a biomarker of pain per se, but rather as a biomarker of a pain mechanism, namely spinal
disinhibition. As loss or attenuation of HRDD is indicative of abnormal spinal inhibitory
processing, identification of an optimal cut off value of HRDD which best delineates
patients with disinhibition as a dominant pain mechanism is paramount. In our ROC
analysis, using the best discriminatory area under the curve value, mean of responses H2–4
and H2–5 at 1 Hz, followed by Youden’s index, we obtained a sensitivity value of 78.57
(confidence interval 63.19–89.70) and 78.57 (confidence 64.06–88.29), respectively. A similar
value, 77.05, was also obtained for specificity. It is, however, unlikely that this balance
provides the best interpretation of the data for our potential biomarker. Our previously
published work [8,15] provides evidence that impaired HRDD demonstrates a degree of
heterogeneity across a cohort of patients with pain, i.e., not all patients with pain have
impaired HRDD. However, impaired HRDD is a highly unique feature to patients with
pain, i.e., no patients without pain fell in the sub-group of patients with highly impaired
(>2SD) HRDD. Therefore, an increased level of specificity (and in turn a reduced level of
sensitivity) may represent a more appropriate cut off value for HRDD. For example, at
100% specificity, HRDD (using mean H2–5 @ 1 Hz) above 66.3 would capture 42.9% of
patients with pain.
Our working hypothesis is that patients identified using this cut off may constitute
a sub-group of patients in whom treatment with spinally acting medication is likely to
be more effective. In our previous work in rodent models of diabetes, spinally adminis-
tered Duloxetine, a serotonin-noradrenaline reuptake inhibitor (SNRI) thought to act by
enhancing spinal inhibition via 5-HT2A receptors [23], was shown to reverse both allodynia
and deficits in HRDD [8]. Indeed, in clinical studies, Duloxetine is effective in treating
painful diabetic neuropathy in a similar proportion of patients identified by our ROC anal-
ysis using the example of 100% specificity [24–26]. One could speculate that the patients
identified in this way might represent those who are most likely to benefit from SNRI-
based pharmacotherapy.
Whilst it may result in a proportion of patients with spinal disinhibition being missed,
selecting a high specificity value—and thus a high likelihood of only including patients
in whom impaired spinal inhibitory processes are a primary pain mechanism—would be
beneficial for enriching clinical trial populations, assessing mechanism-based treatment of
painful diabetic neuropathy, and as a component of studies involving deep phenotyping of
pain [27,28]. For example, mechanistic studies assessing putative peripheral and central
mechanisms of pain generation in combination with spinal fMRI may ultimately pave the
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way towards personalised pain medicine. To achieve this, further biomarker refinement
will be required to segregate patients that respond to particular drugs such as Duloxetine or
Gabapentin, such that HRDD might inform physicians about the likely efficacy of spinally
acting drugs.
Whilst shorter stimulus trains are appropriate, and likely to be more clinically accept-
able, for detecting impairment in HRDD in painful diabetic neuropathy, they may miss the
enhancement of HRDD seen in patients with diabetes who have no pain. Our recent study
suggested that HRDD, and by implication spinal inhibition and pain suppression, may
be enhanced in patients with painless diabetic neuropathy [15]. In the current study the
only stimulation frequency which differentiated patients with diabetic neuropathy without
pain and control subjects was 1 Hz. It is of note that this was only observed in responses
towards the end of the stimulus train; post 6 s. Furthermore, maximal depression of the
H-reflex was reached progressively later throughout the response train, with increasing
stimulus frequency. This may suggest that the degree of HRDD is dependent on time, in
addition to the well-documented dependence on stimulus frequency. These findings may
also indicate that, unlike the impairment in HRDD in painful diabetic neuropathy, which
is evident throughout the stimulus train, longer stimulus trains are likely to be needed
to capture these potential later pain suppressive differences in spinal inhibitory function
seen in painless diabetic neuropathy. Recent studies in the streptozotocin (STZ) rat model
of type I diabetes suggest that the development of spinal disinhibition in diabetes is a
time-dependent process involving both GABAA- and GABAB-mediated responses [29].
Initially deficits in HRDD are not seen because GABAB mediated inhibition appears to
compensate for the reversal in polarity of GABAA. GABAB receptor-mediated hyperpo-
larisation, in contrast to the fast inhibitory signalling mediated by GABAA receptors, is
slow and prolonged [30]. Therefore, one possibility is that in patients with painless diabetic
polyneuropathy, the enhancement of HRDD and spinal inhibition is due to a compensatory
GABAB-mediated hyperpolarisation that takes time to develop during the stimulus train.
Potential limitations of the study include the relatively small cohort of patients and the
fact that a proportion of patients in the painful diabetic neuropathy group were taking anti-
neuropathic pain medication. Furthermore, patients were taking a variety of different anti-
neuropathic pain medications (see results) with diverse mechanisms of action, precluding
a systematic assessment of their effects on HRDD. It is currently not known whether anti-
neuropathic pain medication affects HRDD. One further potential limitation of the study is
that the control group was of significantly lower age than both the painful and painless
diabetic neuropathy groups. It should be recognised, however, that our previous studies
showed no significant correlation between HRDD and age. It also does not affect the ROC
analysis as data from control participants was not used for this analysis.
5. Conclusions
The current study provides a detailed comparison between individual and average
HRDD stimulus responses to distinguish patients with painful diabetic neuropathy, specifi-
cally those whose pain is likely driven by spinal disinhibition. An average of responses
H2–5 provided good to excellent predictive ability at all three frequencies, with 1 Hz
proving optimal. In terms of clinical utility, the shortened train of five stimuli combined
with a moderate stimulation frequency of 1 Hz makes HRDD a valuable tool which can
easily be accommodated in a clinical setting in terms of equipment, time and most impor-
tantly patient tolerability. Longer trains may be required to investigate enhanced inhibitory
processing in the spinal cord in painless diabetic neuropathy.
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